Page 211 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 211
CHAPTER 8
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
Jacoba J. Eertink Martijn W. Heymans Andreas Hüttmann Stefan Müller Sally F. Barrington Robert Carr Tamas Györke Emanuele Zucca Lale Kostakoglu Stefano Fanti Simone Pieplenbosch Otto S. Hoekstra Henrica C.W. de Vet
Coreline N. Burggraaff Ulrich Dührsen Christine Schmitz Pieternella J. Lugtenburg N. George Mikhaeel Sandor Czibor Luca Ceriani Martin Hutchings Annika Loft Sanne E. Wiegers Ronald Boellaard Josée M. Zijlstra
Blood advances. 2021; 5: 2375-2384.
